top of page
News
-
9/23/2026: Mucommune Awarded Contraceptive Research & Development Center from NIH to Advance its Novel, Antibody-Based Non-Hormonal Contraceptives into Clinical Trials
-
9/14/2026: Mucommune Appoints Matthijs Schoots as Vice President, Operations
-
6/10/2026: Mucommune develops long-acting vaginal ring that continuously releases contraceptive antibodies – Kushiro et al., Journal of Controlled Release
-
11/17/2025: Mucommune Awarded ARPA-H Funding to Develop Novel In Vivo CAR-T Therapy for Cancer
-
7/23/2025: UNC, Mucommune develops next-generation contraceptive antibody – Schaefer et al., Advanced Science
-
6/10/2025: Mucommune develops fast-dissolving antibody vaginal tablet for rapid, on-demand protection –
Kushiro et al., Journal of Controlled Release -
11/30/2021: Novel antibody-based vaginal film for rapid, on-demand contraception – Shrestha et al., Proceedings of the National Academy of Sciences (PNAS)
-
8/11/2021: Our lead contraceptive mAb candidate is published in Science Translational Medicine. UNC Chapel Hill Press release. Media coverage: The Scientist, Wired Magazine, MedScape, WRAL TechWire.
-
7/22/2021: Inhalon, our sister company, announces partnership with Celltrion and initiates Phase 1 and 2 clinical trial.
-
3/11/2021: Mucommune in consortium that initiates first-ever clinical trial for a contraceptive mAb (ClinicalTrials.gov, NCT04731818).
More Coming Soon...
bottom of page